Peplomer

Human SARS Coronavirus Spike Glycoprotein Drugs Development Research Report 2022: Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 8, 2022
Infectious Diseases, Pharmaceutical, Health, Molecule, Research, Decision-making, Peplomer, R, Route of administration, Mall of America, Product description, News, Therapy, Human, Key, History, Administration, Research and development, Pharmaceutical industry, Dietary supplement

The "Human SARS coronavirus Spike Glycoprotein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human SARS coronavirus Spike Glycoprotein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Human SARS coronavirus Spike Glycoprotein (E2 or Peplomer Protein or S) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Human SARS coronavirus Spike Glycoprotein (E2 or Peplomer Protein or S) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Human SARS coronavirus Spike Glycoprotein (E2 or Peplomer Protein or S) targeted therapeutics development and features dormant and discontinued projects.

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

Retrieved on: 
Thursday, September 23, 2021
Technology, Research, Infectious Diseases, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Science, Blood, NGS, Animal, Weight loss, La Jolla Institute for Immunology, Risk, RNA, Security (finance), Therapy, Top of the Form (quiz show), USAMRIID, Private Securities Litigation Reform Act, DNA, Doctor of Philosophy, Immunoglobulin G, U.S. Securities and Exchange Commission, Patient, Engineering, Infection, Martek Biosciences Corporation, COVID-19, Twist Bioscience, Biology, CEO, N501Y, Human, Genomics, Antibody, Agriculture, Immunology, Technology, Severe acute respiratory syndrome coronavirus 2, VHH, Synthetic biology, RBD, Silicon, Drug discovery, ACE2, United States Army Medical Research Institute of Infectious Diseases, Peplomer, Čović, Time, Urinary tract infection, Mutation, SEC, Vaccine, Pharmaceutical industry, Twist Biopharma Antibodies, The Coronavirus Immunotherapy Consortium (CoVIC), Twist Bioscience Corporation, TWIST BIOPHARMA ANTIBODIES, THE CORONAVIRUS IMMUNOTHERAPY CONSORTIUM (COVIC), TWIST BIOSCIENCE CORPORATION

TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.

Key Points: 
  • TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.
  • This makes it an important and viable candidate for clinical testing in combination with other antibody therapeutics.
  • TB202-3 binds to a majority of known mutations, with the exception of the L452R mutation present in the Delta and Epsilon variants.
  • Target recognition by VHH single domains, on the other hand, requires just a single domain found on heavy chain only antibody.

LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

 LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

Labcorp Study Suggests COVID-19 Antibodies Remain at Least 10 Months After Infection

Retrieved on: 
Monday, May 24, 2021
MEN, Medical devices, Infectious diseases, Hospitals, Family, Genetics, Consumer, Clinical trials, Cardiology, Diabetes, Biotechnology, AIDS, Health, Women, Pharmaceutical, Seniors, Oncology, Sarbecovirus, Medical specialties, Health, Medicine, Virology, Zoonoses, Bat virome, Peplomer, COVID-19, LabCorp, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.

Key Points: 
  • Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.
  • Our observational analysis provides an encouraging timeline for antibody development and sustainability among the U.S. population, said David Alfego, PhD, Labcorp senior data scientist and the papers lead author.
  • We sincerely hope it sparks more research, helps unearth answers to complex questions and informs critical, post-pandemic planning.
  • Alfego and a team of Labcorp scientists analyzed results from tests used to detect antibodies that guard against spike and nucleocapsid proteins on the SARS-CoV-2 virus.

Global is Going Mobile; Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory

Retrieved on: 
Thursday, May 20, 2021
Variants of SARS-CoV-2, Medical specialties, Branches of biology, Zoonoses, Health, Sarbecovirus, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Peplomer, Virus, Severe acute respiratory syndrome coronavirus, Antibody

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.
  • Investors and security holders are urged to read these documents free of charge on the SEC\'s web site at http://www.sec.gov .
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

Taking the spike out of COVID-19:

Retrieved on: 
Tuesday, April 27, 2021
Health, Fictional characters, Virology, Peplomer, Virus, Spike

\xe2\x80\x9cWithout the spike protein, there is no viral infection.

Key Points: 
  • \xe2\x80\x9cWithout the spike protein, there is no viral infection.
  • If we can do something that disrupts how the spike protein works, then we can prevent the virus from becoming infectious.\xe2\x80\x9d\nScientists all over the world are working on COVID-19\xe2\x80\x94and the spike protein is just one small piece.
  • Then, one pops out \xe2\x80\x9clike a jackknife\xe2\x80\x9d to harpoon into a victim cell\xe2\x80\x94effectively taking command.
  • But its job has a bad effect on us.\xe2\x80\x9d\nScientists know what the spike protein looks like before and after the harpoon effect.

Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

Retrieved on: 
Monday, April 5, 2021
Research, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Medical specialties, Medicine, Clinical medicine, Antiviral drugs, COVID-19 drug development, Monoclonal antibodies, Immunology, Bamlanivimab, Virology, Peplomer, Bamlanivimab/etesevimab, COVID-19

In the right panel, two spike monomers bound in the up and down positions by the bamlanivimab Fab fragments are overlaid.

Key Points: 
  • In the right panel, two spike monomers bound in the up and down positions by the bamlanivimab Fab fragments are overlaid.
  • Over the past four months, bamlanivimab has been used to treat hundreds of thousands of people across the world -- more than any other COVID-19 antibody therapy.
  • Regardless of the state of the spike protein, bamlanivimab has high binding potency to the RBD of SARS-CoV-2 spike protein.
  • 1 AbCelleras Rapid Pandemic Response Platform Contributes to the Worlds First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment.

Webinar: The role of antibody testing as a companion test to SARS-CoV-2 vaccination

Retrieved on: 
Wednesday, March 10, 2021
Medical specialties, Medicine, Branches of biology, Glycoproteins, Virology, Zoonoses, AbC-19 rapid antibody test, Immunology, Coronavirus disease, Peplomer, Severe acute respiratory syndrome coronavirus, Antibody

The nature of testing for the SARS-CoV-2 virus has changed over the course of the pandemic.

Key Points: 
  • The nature of testing for the SARS-CoV-2 virus has changed over the course of the pandemic.
  • Once, antibody tests were predominantly used for charting the spread of infection within communities, but today they are emerging as a key pillar of large-scale immunisation campaigns.
  • Abingdons own antibody test for the virus, the AbC-19 Rapid Test, is a self-contained, highly accurate lateral flow immunoassay designed to give results within 20 minutes at the point of use.
  • The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus.

Halberd's CEO on The Stock Day Podcast Breaking Down 20X Neutralizing Affinity SARS-COV-2 Antibody

Retrieved on: 
Tuesday, March 9, 2021
Medical specialties, Medicine, Clinical medicine, Immunology, Virology, COVID-19 drug development, Biotechnology, Immune system, Monoclonal antibody, Peplomer, Coronavirus disease, Antibody

CEO and Chairman of the Company, William A Hartman, joined Stock Day host Everett Jolly.

Key Points: 
  • CEO and Chairman of the Company, William A Hartman, joined Stock Day host Everett Jolly.
  • Jolly began the interview by commenting on a recent announcement regarding the Company's proprietary monoclonal antibody against the SARS-COV-2 Spike protein, which demonstrated 20 times greater neutralizing affinity compared to their original antibody.
  • "In order to bring any product forward that requires FDA approval, you're talking about millions of dollars and potentially several years.
  • "We're going to work our way towards working with COVID, where we already have a much stronger antibody," continued Hartman.